Serono Broadens Research Pipeline With ZymoGenetics Alliance
This article was originally published in The Pink Sheet Daily
Executive Summary
Serono will pay over $81 mil. upfront for access to ZymoGenetics’ therapeutic protein research. The deal includes a license to products based on three proteins that could expand Serono’s presence in inflammation and autoimmune disease.
You may also be interested in...
ZymoGenetics’ rhThrombin Expected To Launch In 2007
Company anticipates recombinant human product could take market share away from competing King biologic.
ZymoGenetics’ rhThrombin Expected To Launch In 2007
Company anticipates recombinant human product could take market share away from competing King biologic.
Novo Nordisk Licenses Factor XIII Portfolio From ZymoGenetics
The company is discussing the pivotal trial program for Factor XIII with FDA following the agreement. Novo Nordisk expects to initiate clinical studies in fibrinolysis-induced bleeding next year.